Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb CoLIM:BMY 57 5-Year Yield-on-Cost % is 5.99 as of Jul. 22, 2026, which is 44% above its 10-year median of 4.15. GuruFocus rates LIM:BMY with a GF Score™ of 57/100 and a GF Value™ of $51.53 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 513 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 76.41% on this metric.
The historical rank and industry rank for Bristol-Myers Squibb Co's 5-Year Yield-on-Cost % or its related term are showing as below:
LIM:BMY'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.74 Med: 4.15 Max: 8.12
Current: 5.99
During the past 13 years, Bristol-Myers Squibb Co's highest Yield on Cost was 8.12. The lowest was 2.74. And the median was 4.15.
LIM:BMY's 5-Year Yield-on-Cost % is ranked better than 76.41% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs LIM:BMY: 5.99
Bristol-Myers Squibb Co (LIM:BMY) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Bristol-Myers Squibb Co 5-Year Yield-on-Cost % Related Terms
LIM:BMY vs PFE, GILD, AMGN: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's 5-Year Yield-on-Cost % falls into.
Bristol-Myers Squibb Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Bristol-Myers Squibb Co (LIM:BMY) has a 5-Year Yield-on-Cost % of 5.99 as of Jul. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bristol-Myers Squibb Co and its competitors. This is 44% above median its historical median of 4.15. Over the past decade, Bristol-Myers Squibb Co's 5-Year Yield-on-Cost % has ranged from 2.74 to 8.12. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #121 out of 513 companies in the Drug Manufacturers industry, placing it in the top 23.6%.
Is Bristol-Myers Squibb Co's 5-Year Yield-on-Cost % too high?
Bristol-Myers Squibb Co's current 5-Year Yield-on-Cost % of 5.99 is 44% above median its 10-year median of 4.15. Over the past 10 years, this metric has ranged from a low of 2.74 to a high of 8.12. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Bristol-Myers Squibb Co's value of 5.99 is 161.6% above this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #121 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's 5-Year Yield-on-Cost % compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #121 out of 513 companies for 5-Year Yield-on-Cost %. This places Bristol-Myers Squibb Co in the top 24% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.29. Bristol-Myers Squibb Co's value of 5.99 is 161.6% above this benchmark. Historically, Bristol-Myers Squibb Co's own 5-Year Yield-on-Cost % has ranged from 2.74 to 8.12 over the past decade. While the company's 10-year median is 4.15 vs. the industry median of 2.29, Bristol-Myers Squibb Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current 5-Year Yield-on-Cost % of 5.99 is 161.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current 5-Year Yield-on-Cost % is 5.99, which is 44% above median its own 10-year median of 4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $51.53, compared to a current price of $56.98 — trading 10.6% above its estimated fair value. The current 5-Year Yield-on-Cost % is 5.99, which is 44% above median its 10-year median of 4.15 and 161.6% above the Drug Manufacturers industry median of 2.29. Bristol-Myers Squibb Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current 5-Year Yield-on-Cost % is 5.99 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $56.98 is trading 10.6% above its estimated GF Value™ of $51.53.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for LIM:BMY:
5-Year Yield-on-Cost %: 5.99 (44% above median its 10-year median of 4.15)
GF Value™: $51.53 vs. price of $56.98 (10.6% above fair value)
Industry Position: 161.6% above the Drug Manufacturers median (#121 of 513)
No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
57GF Score
Get the complete analysis for LIM:BMY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIM:BMY has been successfully added to your 
